Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Ovarian Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Ovarian Cancer
    TopAbstracts in Ovarian Cancer 10/21/2009 - (DGNews)
    Neoadjuvant Chemotherapy Confers Important Benefits in Advanced Ovarian Cancer: Presented at ACS - (DGDispatch)
    Dose-Dense Chemotherapy Improves Survival in Advanced Ovarian Cancer - (DGNews)
    TopAbstracts in Ovarian Cancer 09/23/2009 - (DGNews)
    FDA Approves Test to Help Detect Ovarian Cancer - (DGNews)

    News archive

     Recent webcasts/CME - Ovarian Cancer
  • Current Therapeutic Options and Clinical Issues in Recurrent Ovarian Cancer: Where Do We Stand?
  • Ovarian Cancer: Designed for the Primary Care Physician

    Webcasts/CME archive

     Recent cases - Ovarian Cancer
      Leser-Trelat Sign Presenting in a Patient with Ovarian Cancer: A Case Report
      Large Family with Both Parents Affected by Distinct BRCA1 Mutations: Implications for Genetic Testing
      Primary Hepatic Embryonal Sarcoma Masquerading as Metastatic Ovarian Cancer
      Choroidal Eye Metastases from (Recurrent) Primary Peritoneal Carcinoma: Case Report and Review of the Literature
      A Case of Meigs Syndrome Mimicking Metastatic Breast Carcinoma

      Cases archive
        




      my personal edition > ovarian cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Thalidomide Shows Promise in Ovarian Cancer Treatment: Presented at SGO

      By Norra MacReady

      PALM SPRINGS, F.L. -- March 24, 2006 -- Adding thalidomide to a topotecan regimen for recurrent ovarian cancer significantly enhances therapeutic response and increases progression-free survival without increasing incidence of toxicity, researchers reported here at the 37th Annual Meeting of the Society of Gynecologic Oncologists (SGO).

      Levi S. Downs, Jr., MD, medical director, Women's Health Center, University of Minnesota Medical School and Cancer Center, Minneapolis, Minnesota, United States, discussed the results in a presentation on March 24th.

      In an intention-to-treat analysis, 47% of 30 patients who received thalidomide plus topotecan experienced a complete or partial response, significantly more than the 21% of 39 patients who received topotecan alone (P =.036). These patients were 10.4 times as likely to achieve some type of response as the women who received monotherapy (P =.043). Median disease-free survival among women receiving both drugs was 6 months, compared to 4 months among women on the single-drug regimen (P =.02).

      Thalidomide may exert this effect through its antiangiogenic and immunomodulatory properties, Dr. Downs explained. It inhibits the activity of basic fibroblast growth factor and angiogenesis induced by vascular endothelial growth factor. It also stimulates the production of interferon gamma and certain interleukins. Topotecan is a cytotoxic agent that inhibits topoisomerase I, and there is evidence that it inhibits the growth of endothelial cells.

      Dr. Downs said his findings suggest that new molecules under development that act as antiangiogenic and immunomodulatory agents – such as thalidomide -- may be valuable adjuncts to traditional cytotoxic therapy for women with ovarian cancer.

      Initially, the study enrolled 75 women from seven different research sites. Of those, 41 women were randomized to receive topotecan alone as a 30-minute, intravenous infusion of 1.25 mg/m2 for 5 consecutive days every 21 days. Two women dropped out of the study before undergoing any treatment.

      Thirty-four women were randomized to receive topotecan plus thalidomide, starting with an oral dose of 200 mg/day and increased by 100 mg/day every 7 days until adverse effects became too onerous. Four patients dropped out of that arm of the study.

      Neither the patients nor the investigators were blinded as to treatment arm.

      The incidence of toxicity was similar between the groups. Of the women receiving the combination therapy, 87% developed neutropenia, 20% developed thrombocytopenia, and 13% developed anemia. In the single-treatment arm, it was 72%, 36%, and 23%, respectively.

      Fatigue and somnolence are common toxicities associated with thalidomide, but their incidence was not increased in this study, Dr. Downs said.

      He concluded, "thalidomide and other antiangiogenic and immunomodulatory agents warrant further study for women with recurrent ovarian cancer, particularly in combination with cytotoxic agents."


      [Presentation title: A Prospective Randomized Trial of Thalidomide with Topotecan Compared to Topotecan Alone in Women with Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma. Presentation 19]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send